Amy Schacterle - 05 Nov 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Chief Regulatory Officer
Signature
/s/ Derek Meisner, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
05 Nov 2024
Net transactions value
$0
Form type
4
Filing time
06 Nov 2024, 17:27:14 UTC
Next filing
07 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +340,000 $0.000000 340,000 05 Nov 2024 Common Stock 340,000 $2.95 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option shall vest and become exercisable on November 5, 2025, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest and become exercisable each month thereafter, subject to Reporting Person continuing to provide service through each such date.